Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
11/17/1999Meridian Diagnostics Reports Year-End Operating Results and Increases Dividend Rate
CINCINNATI--(BW HealthWire)--Nov. 17, 1999--Meridian Diagnostics, Inc. (Nasdaq:KITS) Net sales increased 64% Per share earnings of $0.42 before non-recurring merger integration and purchased research and development costs EBITDA of $12.3 million Annual cash dividend rate increased 20% to $0.24 per share based on strong business outlook for and expectation of record net income for fiscal 2000 Meridian Diagnostics, Inc. (Nasdaq:KIT... 
 Printer Friendly Version
10/22/1999HCFA Announces Coverage of Meridian Diagnostics New Ulcer Test
CINCINNATI--(BW HealthWire)--Oct. 22, 1999--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today reported that the United States Health Care Financing Administration (HCFA) has announced their national coverage policy decision relating to Meridian Diagnostics' new non-invasive ulcer test, Premier Platinum HpSA(TM)(HpSA). The purpose of the HpSA test, which was cleared by the Food and Drug Administration (FDA) to market in May 1998, is to aid in the diagnosis of H... 
 Printer Friendly Version
9/28/1999Meridian's Stomach Ulcer Test Unaffected by Common Medications
CINCINNATI--(BW HealthWire)--Sept. 28, 1999--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq: KITS) today announced that The American Journal of Gastroenterology (AJG) published an article entitled, ''Effects of Acid Suppression and Bismuth Medications on the Performance of Diagnostic Tests for Helicobacter pylori Infection,'' (Luis E. Bravo, M.D., et. al.). This article reports on a study designed to investigate whether acid suppression and bismuth medications interfere with the... 
 Printer Friendly Version
8/11/1999Meridian's New Rapid Test for E. coli Infections Receives FDA Clearance to Market
CINCINNATI--(BW HealthWire)--Aug. 11, 1999--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today announced that it has received clearance from the United States Food and Drug Administration (FDA) to market ImmunoCard STAT!(TM) E. coli O157 Plus. This rapid test will detect the most prevalent toxigenic strain of E. coli, E. coli O157:H7, which is often transmitted via ground beef, vegetables and other foods. E. coli O157 infects up to 1 million individuals each year in the U... 
 Printer Friendly Version
7/22/1999Meridian Diagnostics Announces Third Quarter and Nine Months Operating Results, Reports Operations At Gull Laboratories Continue to Exceed Expectations, Declares Dividend
CINCINNATI--(BW HealthWire)--July 22, 1999--Meridian Diagnostics, Inc. (Nasdaq:KITS) today announced net sales of $13,825,000 for the third fiscal quarter ended June 30, 1999, compared to net sales of $8,226,000 for the same period of the prior fiscal year, an increase of $5,599,000, or 68%. Net earnings, excluding the after-tax impact of merger integration costs of $339,000 ($0.03 per share) in connection with the recent acquisition of Gull Laboratories, were $1,684,000 or $0.12 per shar... 
 Printer Friendly Version
7/14/1999Meridian Test Aids in Diagnosis of Toxic E. coli Outbreak
CINCINNATI--(BW HealthWire)--July 14, 1999--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today announced that its Premier EHEC test was used to diagnose young adults impacted by an outbreak of toxigenic E. coli in the state of Texas. It has been determined that the bacteria Escherichia coli (E. coli) strain O111 was the cause of illness in more than 52 individuals. Specimens were tested for E. coli O157:H7, the more commonly-known form of E. coli, but produced a negative... 
 Printer Friendly Version
7/12/1999Meridian Type-Specific Herpes Tests Receive FDA Clearance to Market
CINCINNATI--(BW HealthWire)--July 12, 1999--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today announced that it has received clearance from the United States Food and Drug Administration (FDA) to market two diagnostic tests for the herpes simplex virus. These tests, Premier(TM) Type-Specific HSV-1 IgG ELISA Test and Premier(TM) Type-Specific HSV-2 IgG ELISA Test, are the first medical tests cleared by the FDA that have been proven to be able to distinguish Herpes Simplex... 
 Printer Friendly Version
7/7/1999The Lancet Publishes Article on Meridian's HpSA Test for Stomach Ulcers
CINCINNATI--(BW HealthWire)--July 7, 1999--Meridian Diagnostics, Inc., (Meridian) (Nasdaq:KITS) today announced that the esteemed medical journal, The Lancet, published an article entitled, "Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay," (Dr. D. Vaira, et. al.). This article reports on a study designed to confirm the accuracy of Meridian's Premier Platinum HpSA(TM) (HPSA), the newly developed test for the detection of the H. pylori antigen which ... 
 Printer Friendly Version
6/29/1999William J. Motto, CEO Of Meridian Diagnostics, Receives 1999 Entrepreneur of the Year Award
    Business Editors, Health & Medical Writers     CINCINNATI--(BW HealthWire)--June 29, 1999--Meridian Diagnostics, Inc., (Nasdaq:KITS), today announced that William J. Motto, Chief Executive Officer, received The Cincinnati/Northern Kentucky 1999 Ernst & Young Entrepreneur of the Year Award in the Technology division. This prestigious Award, given annually to owners and managers, honors the area's entrepreneurs consisting of 26 total finalists. ... 
 Printer Friendly Version
4/21/1999Meridian Diagnostics Announces Second Quarter and First Half Operating Results, Reports Profitable Operations At Gull Laboratories, and Declares Regular Cash Dividend
    Business Editors, Health/Medical Writers     CINCINNATI--(BW HealthWire)--April 21, 1999--Meridian Diagnostics, Inc. (Nasdaq:KITS) today announced net sales of $14,654,000 for the second quarter of fiscal 1999 ended March 31, 1999, compared to net sales of $9,542,000 for the same period of the prior fiscal year, an increase of $5,112,000, or 54%. Net earnings, excluding the after-tax impact of merger integration costs of $425,000 ($0.03 per ... 
 Printer Friendly Version
1/28/1999Meridian Announces Operating Results Including Record Sales for the First Quarter of Fiscal 1999
CINCINNATI--(BW HealthWire)--Jan. 28, 1999--Meridian Diagnostics, Inc. (Nasdaq:KITS) today announced net sales for the first fiscal quarter ended December 31, 1998 of $11,720,000, compared to net sales of $8,448,000, during the same period of the prior fiscal year. Net earnings, excluding the after-tax impact of one-time restructuring and integration costs of $280,000 ($0.02 per share) associated with the acquisition of Gull Laboratories on November 5, 1998, were $834,000 ($0.06 per share... 
 Printer Friendly Version